Latest News
Aclarion, Inc.
- Aclarion study finds Nociscan agrees with discography in 87% of cases
- Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
- Aclarion at LD Micro main event: pushing Nociscan toward scale By Investing.com
- Aclarion reports 85% scan volume growth in Q3 2...
- Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth And Advancing Clinical Program In Third Quarter 2026
- Aclarion Reports 85% Q3 Scan Volume Growth, Expands CLARITY Trial and Highlights New European Spine Journal Publication
- Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
- A 300-patient back-pain study is enrolling at 11 sites. Aclarion says $14.2 million in cash can fund it.
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
- Aclarion broadens CLARITY trial criteria to spe...
- A back-pain trial changed who can qualify at 9 of 11 sites. Aclarion expects faster enrollment.
- Aclarion at Lytham Partners fall investor conference: growth and proof By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →